Add like
Add dislike
Add to saved papers

Basic Fibroblast Growth Factor Improved Angiogenesis of Vitrified Human Ovarian Tissues after in vitro Culture and Xenotransplantation.

Cryo Letters 2017 May
BACKGROUND: Basic fibroblast growth factor is a potent angiogenic factor.

OBJECTIVE: To study the concentration and in vitro culture time of bFGF that maximize the angiogenesis for transplanted human ovarian tissues.

MATERIALS AND METHODS: Vitrified and rewarmed human ovarian tissues were cultured in vitro with bFGF (0, 25, 50, 100, 150 and 200 ng/ml) for different periods (1 h, 2 d, 5 d and 7 d) before transplantation. The effect of bFGF on follicle survival was studied by evaluating the pregraft group, control group (no bFGF) and bFGF-treated group. CD34, Ki-67 and AC-3 immuno-histochemical (IHC) staining and histological analysis was used to evaluate angiogenesis, proliferration, apoptosis and follicular quantity.

RESULTS: Treatments with 100 and 150 ng/ml bFGF improved the angiogenesis for grafted human ovarian tissues after in vitro culture for 2 days. The proliferation and survival of follicles were significantly increased.

CONCLUSION: bFGF improved the quality of vitrified-warmed human ovarian tissues after transplantation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app